Vaccine design by immunoinformatics against HCV: Chemical characterization and prediction of T-cell epitopes
DOI:
https://doi.org/10.33448/rsd-v10i16.22994Keywords:
Hepatitis C; Bioinformatics; Vaccine.Abstract
Hepatitis C is a disease that affects the liver causing its inflammation, reaching thousands of people every year, however currently there are no vaccines for the virus responsible for the disease, HCV, although studies are already carried out on its feasibility. Therefore, reverse vaccinology can be of great help in detecting promising targets for use as a vaccine antigen and concomitantly formulating an effective vaccine. The respective work aims to obtain relevant data for the design of promising vaccines against HCV through the use of bioinformatics tools. Therefore, after the virus sequences were obtained from the National Center for Biotechnological Information (NCBI), analyzes of the antigenic potential were carried out using VaxiJen v.2.0. and from ANTIGENpro, together with AlgPred, the allergenic potential was verified, soon after the proteins were verified and selected, they would proceed to the next steps where they were submitted for the characterization of the physicochemical properties, through and the prediction of T cell epitopes was performed on NetTepi. Among the results obtained, it can be noted that the E2 protein was the only one to demonstrate allergenicity, whereas the E1 protein did not present antigenic potential and the other proteins were classified as unstable, following only the NS4a protein for prediction of T cell epitopes.
References
Adhikari, U. K., Tayebi, M., & Rahman, M. M. (2018). Immunoinformatics approach for epitope-based peptide vaccine design and active site prediction against polyprotein of emerging oropouche virus. Journal of immunology research, 2018.
Axley, P., Ahmed, Z., Ravi, S., & Singal, A. K. (2018). Hepatitis C virus and hepatocellular carcinoma: a narrative review. Journal of clinical translational hepatology, 6(1), 79. https://doi.org/10.14218/JCTH.2017.00067
Bulut, M. E., Topalca, U. S., Murat, A., Teke, L., Canalp, H. Z., Ocal, M., & Bayraktar, B. (2021). HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul. The Medical Bulletin of Sisli Etfal Hospital, 55(1), 86.
Calis, J. J., Maybeno, M., Greenbaum, J. A., Weiskopf, D., De Silva, A. D., Sette, A., . . . Peters, B. (2013). Properties of MHC class I presented peptides that enhance immunogenicity. PLoS computational biology, 9(10), e1003266.
Castelli, M., Cappelletti, F., Diotti, R. A., Sautto, G., Criscuolo, E., Dal Peraro, M., & Clementi, N. (2013). Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. Clinical Developmental Immunology, 2013.
Castro, A., Ozturk, K., Pyke, R. M., Xian, S., Zanetti, M., & Carter, H. (2019). Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes. BMC medical genomics, 12(6), 1-13.
Deng, L., Hernandez, N., Zhong, L., Holcomb, D. D., Yan, H., Virata, M. L., . . . Struble, E. J. P. o. t. N. A. o. S. (2021). A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization. 118(28).
El Abd, Y. S., Tabll, A. A., El Din, N. G. B., Hosny, A. E.-D. S., Moustafa, R. I., El-Shenawy, R., . . . El-Awady, M. K. (2011). Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. Virology Journal, 8(1), 1-12.
Gasteiger, E., Hoogland, C., Gattiker, A., Wilkins, M. R., Appel, R. D., & Bairoch, A. (2005). Protein identification and analysis tools on the ExPASy server. The proteomics protocols handbook, 571-607.
Gong, Y., & Cun, W. J. I. j. o. m. s. (2019). The role of apoe in HCV infection and comorbidity. 20(8), 2037.
Kaur, K., Gandhi, M. A., & Slish, J. (2015). Drug-drug interactions among hepatitis C virus (HCV) and human immunodeficiency virus (HIV) medications. Infectious diseases therapy, 4(2), 159-172.
Leow, C. Y., Kazi, A., Ismail, C. M. K. H., Chuah, C., Lim, B. H., Leow, C. H., & Singh, K. K. B. (2020). Reverse vaccinology approach for the identification and characterization of outer membrane proteins of Shigella flexneri as potential cellular-and antibody-dependent vaccine candidates. Clinical experimental vaccine research, 9(1), 15-25.
Li, H.-C., & Lo, S.-Y. (2015). Hepatitis C virus: Virology, diagnosis and treatment. World journal of hepatology, 7(10), 1377. https://doi.org/10.4254/wjh.v7.i10.1377
Li, W., Joshi, M. D., Singhania, S., Ramsey, K. H., & Murthy, A. K. (2014). Peptide vaccine: progress and challenges. Vaccines, 2(3), 515-536.
Lund, O., Nielsen, M., Kesmir, C., Petersen, A. G., Lundegaard, C., Worning, P., . . . Justesen, S. (2004). Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics, 55(12), 797-810.
Magnan, C. N., Zeller, M., Kayala, M. A., Vigil, A., Randall, A., Felgner, P. L., & Baldi, P. J. B. (2010). High-throughput prediction of protein antigenicity using protein microarray data. 26(23), 2936-2943.
Martinez, M. A., & Franco, S. J. V. (2021). Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses, 13(1), 41.
Meuleman, T. J., Cowton, V. M., Patel, A. H., & Liskamp, R. M. (2021). Design and synthesis of HCV-E2 glycoprotein epitope mimics in molecular construction of potential synthetic vaccines. Viruses, 13(2), 326.
Nascimento, I., & Leite, L. (2012). Recombinant vaccines and the development of new vaccine strategies. Brazilian journal of medical biological research, 45, 1102-1111.
Ong, E., Wong, M. U., Huffman, A., & He, Y. J. F. i. i. (2020). COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. 11, 1581.
Panahi, H. A., Bolhassani, A., Javadi, G., & Noormohammadi, Z. (2018). A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins. PloS one, 13(10), e0205933.
Pham, L. V., Ramirez, S., Carlsen, T. H., Li, Y. P., Gottwein, J. M., Bukh, J. (2017). Efficient hepatitis C virus genotype 1b core-NS5A recombinants permit efficacy testing of protease and NS5A inhibitors. Antimicrobial agents chemotherapy, 61(6).
Saha, S., & Raghava, G. (2007). Prediction of allergenic proteins and mapping of IgE epitopes in allergens.
Sawada, L., Pinheiro, A. C. C., Locks, D., Pimenta, A. d. S. C., Rezende, P. R., Crespo, D. M., . . . Oliveira Filho, A. B. d. (2011). Distribution of hepatitis C virus genotypes among different exposure categories in the State of Pará, Brazilian Amazon. Revista da Sociedade Brasileira de Medicina Tropical, 44, 8-12.
Schuch-Goi, S. B., Scherer, J. N., Kessler, F. H. P., Sordi, A. O., Pechansky, F., & von Diemen, L. (2017). Hepatitis C: clinical and biological features related to different forms of cocaine use. Trends in psychiatry psychotherapy, 39, 285-292.
Sirskyj, D., Diaz‐Mitoma, F., Golshani, A., Kumar, A., & Azizi, A. (2011). Innovative bioinformatic approaches for developing peptide‐based vaccines against hypervariable viruses. Immunology cell biology, 89(1), 81-89.
Stamataki, Z. J. E. r. o. a.-i. t. (2010). Hepatitis C infection of B lymphocytes: more tools to address pending questions. 8(9), 977-980.
Trolle, T., & Nielsen, M. (2014). NetTepi: an integrated method for the prediction of T cell epitopes. Immunogenetics, 66(7), 449-456.
Yasmin, T., & Nabi, A. N. (2016). B and T cell epitope‐based peptides predicted from evolutionarily conserved and whole protein sequences of Ebola virus as vaccine targets. Scandinavian journal of immunology, 83(5), 321-337.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Fabiano Ricardo Fontes Santos; Esther Santos Santana; Daniela Droppa-Almeida
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
